Welcome to our dedicated page for PERKINELMER news (Ticker: PKI), a resource for investors and traders seeking the latest updates and insights on PERKINELMER stock.
Overview of PerkinElmer Inc.
PerkinElmer Inc. is a globally recognized scientific instrumentation and solutions provider that serves the needs of researchers, clinicians, and scientists in diagnostics, life sciences, and applied markets. With decades of expertise, the company combines state-of-the-art technology with deep industry knowledge to deliver instruments and software that empower precise and early insights in analytical and diagnostic processes.
Core Business Areas
PerkinElmer specializes in multiple business areas, including:
- Diagnostics: Offering advanced tools and methodologies designed to support early disease detection and accurate diagnostics.
- Life Sciences: Providing instrumentation and support services that enhance biological research, drug discovery, and genomic studies.
- Food and Applied Markets: Delivering practical solutions tailored to food safety, environmental monitoring, and quality control.
Business Model and Revenue Generation
The company operates by integrating advanced science and technology with customer-focused services, generating revenue through direct sales of high-performance analytical instruments, licensing of proprietary technologies, and ongoing service contracts. The business model emphasizes long-term customer partnerships and continuous innovation, which are vital in meeting the evolving needs of global research communities.
Market Position and Competitive Landscape
Positioned as a significant player in the scientific instrumentation sector, PerkinElmer competes with other global providers by offering an extensive portfolio of integrated solutions. Its competitive edge stems from its deep technical expertise, robust customer service, and strategic investments in research and development. This approach not only addresses current market challenges but also establishes a broad framework that supports complex research endeavors and regulatory needs.
Technological Innovation and Expertise
At its core, PerkinElmer leverages cutting-edge technologies to enable breakthrough discoveries in science and healthcare. The company continuously evolves its product offerings through innovation in instrument design, software integration, and application-specific solutions. These innovations are a direct result of its commitment to deep market insight and technical expertise, ensuring that its customers benefit from the latest advances in scientific research.
Global Reach and Impact
With a presence in numerous countries worldwide, the company functions as a key enabler in global research efforts. By providing technologies that support both clinical and research applications, PerkinElmer contributes significantly to improving healthcare outcomes and advancing scientific understanding. Its global footprint allows it to serve a diverse array of industries, reinforcing its role as a vital partner in enhancing quality of life through scientific progress.
Commitment to Quality and Customer Partnership
PerkinElmer is dedicated to building strategic partnerships with its customers, offering tailored support and service solutions that meet the specific requirements of complex research and diagnostic projects. This commitment is reflected in its holistic approach to customer engagement, combining product excellence with expert consultancy and robust technical assistance.
Conclusion
In summary, PerkinElmer Inc. encapsulates a sophisticated blend of innovation, market insight, and operational excellence. It remains an influential entity in the scientific and healthcare sectors by consistently providing analytical instrumentation and solutions that empower users to achieve early and accurate results. The company’s ability to integrate advanced technology with practical applications makes it an indispensable partner for global research institutions and healthcare providers alike.
Revvity (NYSE: RVTY) has announced the launch of EUROIMMUN's CE-marked Anti-Measles Virus ELISA 2.0 (IgG), expanding its infectious disease diagnostics portfolio. This novel assay is designed to support measles virus infection diagnosis and immune status determination.
The test is notable as the first commercial assay validated for dried blood spots (DBS) alongside traditional serum and plasma samples. DBS testing requires only fingertip blood droplets on paper cards, offering advantages in routine testing, studies, and regions with medical infrastructure.
The assay addresses a market gap as the first commercial solution for detecting anti-measles virus IgG antibodies using DBS samples, eliminating the need for laboratories to conduct their own validations. The test can be processed both manually and automatically using EUROIMMUN's scalable solutions.
Revvity (NYSE: RVTY) has secured a favorable ruling from the Massachusetts Superior Court, which will issue a permanent injunction enforcing its agreements with Cloud Software Group (CSG) regarding Spotfire® software. This follows a preliminary injunction from April 2024 and ensures continued access to Spotfire software and support for Revvity and its customers through 2034.
The ruling maintains Revvity's position as the exclusive provider of Spotfire in research and clinical markets, safeguarding operational continuity and service quality for customers. The company expressed satisfaction with the court's decision to uphold the agreements and emphasized its commitment to maintaining service reliability.
Revvity (NYSE: RVTY) has announced its participation in four major investor conferences during March 2025. The company's leadership team will present at the following events:
- 46th Annual Raymond James Institutional Investor Conference (March 3, 7:30 a.m. ET) featuring CFO Max Krakowiak
- TD Cowen 45th Annual Health Care Conference (March 4, 9:10 a.m. ET) with CEO Prahlad Singh
- Leerink Partners Global Healthcare Conference (March 11, 8:00 a.m. ET) featuring CEO Prahlad Singh
- KeyBanc Capital Markets Healthcare Forum (March 19, 9:00 a.m. ET) with Steve Willoughby, SVP of Investor Relations
The presentations will provide updates on the company's strategic priorities. Live audio webcasts will be available on the company's website, with replays accessible for at least 30 days following the events.
Revvity (NYSE: RVTY) reported strong fourth quarter 2024 results with revenue reaching $729 million, representing 5% reported growth and 6% organic growth. The company's Q4 GAAP EPS was $0.78, while adjusted EPS from continuing operations reached $1.42.
For full year 2024, GAAP revenue was $2,755 million compared to $2,751 million in 2023. The Life Sciences segment reported Q4 revenue of $336 million (5% growth), while Diagnostics segment achieved $393 million (4% growth).
Looking ahead, Revvity initiated its 2025 guidance with projected revenue of $2.80-$2.85 billion and adjusted EPS of $4.90-$5.00.
Revvity (NYSE: RVTY) announced that its Board of Directors has declared a quarterly dividend of $0.07 per share of common stock. The dividend will be paid on May 9, 2025, to shareholders of record as of the close of business on April 18, 2025.
Revvity (NYSE: RVTY) has announced a strategic agreement with Element Biosciences to develop and commercialize an in vitro diagnostic (IVD) workflow solution for neonatal sequencing. The collaboration combines Revvity's expertise in newborn screening and rare disease detection with Element's AVITI™ sequencing system technology.
The partnership will deliver both an immediate research use only (RUO) version and a comprehensive IVD solution for newborn sequencing. The workflow includes Revvity's sample collection devices, dried blood spot punchers, automated nucleic acid extractors, liquid handlers, NGS library preparation kits with curated NGS panels, and software for variant calling data analysis and interpretation.
This initiative builds upon Revvity's recent introduction of an automated next-generation sequencing workflow for newborn sequencing research and supports Element's progress toward regulatory approval of their benchtop AVITI™ sequencing system.
Revvity (NYSE: RVTY) has announced its upcoming fourth quarter and full year 2024 financial results release, scheduled for January 31, 2025, before market open. The company will host a conference call at 8:00 a.m. ET on the same day.
In preliminary Q4 2024 results, Revvity expects reported revenue growth of 5% and organic revenue growth of 6% compared to the previous year, projecting quarterly revenue of approximately $730 million. The company anticipates meeting or exceeding its full year 2024 adjusted earnings per share guidance previously provided on November 4, 2024.
Additionally, CEO Prahlad Singh will present at the 43rd annual J.P. Morgan Healthcare Conference on January 13, 2025, at 8:15 a.m. PT.
Revvity (NYSE: RVTY) has received FDA 510(k) clearance for EUROIMMUN's automated chemiluminescence-based immunoassay (ChLIA) test for free testosterone. This marks a significant milestone as the first FDA-cleared test for direct quantitative measurement of free testosterone levels in human serum or plasma.
The innovative assay, which runs on the company's iSYSTM or i10TM instruments, delivers results in just 48 minutes with a throughput of nearly 60 tests per hour. The test features monoclonal antibodies for consistent performance and specificity across batches.
This advancement enhances diagnostic capabilities for conditions including hypogonadism, impotence, polycystic ovarian syndrome (PCOS), and other androgenital syndromes, offering a user-friendly, random-access platform solution for direct free testosterone measurement.
Revvity (NYSE: RVTY) has announced its participation in the 43rd annual J.P. Morgan Healthcare Conference scheduled for January 13, 2025, at 8:15 a.m. PT in San Francisco. President and CEO Prahlad Singh will present an update on the company's strategic priorities and overall direction. The presentation will be accessible through a live audio webcast, with a replay available on the Revvity Investor Relations website for a minimum of 30 days following the event.
Revvity (NYSE: RVTY) announced an expanded collaboration with Genomics England to advance genomic initiatives across the UK. The partnership focuses on the Generation Study, a research program aiming to screen up to 100,000 newborns for 200 rare genetic conditions in England. Through its Omics laboratory in Manchester, Revvity will extract DNA from cord blood samples using the chemagic 360™ instrument. The collaboration aims to advance early detection of genetic conditions in newborns while also supporting the development of genomics talent across the UK region.